PharmTech Drug Digest 11.20
|Articles|November 2, 2016

Pharmaceutical Technology

  • Pharmaceutical Technology-11-02-2016
  • Volume 40
  • Issue 11

Integrated Membrane for Single-Use Filtration Assemblies

Sartorius Stedim Biotech’s polyethersulfone membrane is now integrated into two new, sterile Sartocon benchtop and production-scale filtration assemblies.

Sartorius Stedim Biotech’s (SSB) polyethersulfone membrane (PESU) is now integrated into two new, sterile Sartocon benchtop and production-scale filtration assemblies. The fully enclosed design makes the Sartocon assemblies ideal for safely purifying vaccines and recombinant proteins, as well as monoclonal antibody manufacturing. The assemblies are suitable for use in cGMP environments for process development, clinical trials, and small-scale production batches.

Because the Sartocon assemblies are designed with the same hydrodynamic flow path as SSB’s larger production-scale filter devices, and all device materials and accessories are manufactured to the same industrial quality-assured specifications, linear scale-up, and process transfer is simple. The PESU membrane inside the Sartocon assemblies is available in several sizes, 10-300 KDa molecular weight cut-offs, and is robust enough for use in broad pH and temperature ranges. These features, combined with the Sartocon assemblies’ single-use design, prevent product cross-contamination.

Sartorius Stedim Biotech


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.